Physician profile
Waheed Gul
NPI 1205813763
$3,829.08
in general payments reported to CMS, 2019-2025
21 companies · $659 in 2025
The $659 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $587 · 2020: $147 · 2021: $43.02 · 2022: $614 · 2023: $1,204 · 2024: $575 · 2025: $659.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,615 · Travel and Lodging: $745 · Education: $78.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,614.79 |
| Travel and Lodging | $745.16 |
| Education | $78.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,058.10 | 2023-2024 | Spyglass, Resolution 360 Clip, Spyglass |
| Janssen Biotech, INC. | $742.72 | 2019-2025 | Tremfya, Stelara |
| Abbvie INC. | $698.41 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $235.47 | 2019-2020 | |
| Gilead Sciences, INC. | $193.84 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $138.78 | 2019-2022 | |
| Ucb, INC. | $128.53 | 2019 | |
| Celgene Corporation | $117.69 | 2019-2023 | Zeposia |
| Pfizer INC. | $89.49 | 2019 | |
| Qol Medical, LLC | $71.02 | 2024-2025 | Sucraid, Sucraid |
| Olympus America INC. | $67.04 | 2020 | |
| Phathom Pharmaceuticals, INC. | $41.70 | 2025 | Voquezna |
| Genzyme Corporation | $40.23 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $35.85 | 2022 | |
| Micro-Tech Endoscopy USA, INC. | $35.34 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $33.77 | 2022-2023 | |
| Aimmune Therapeutics, INC. | $32.78 | 2025 | Vowst |
| E.R. Squibb & Sons, L.L.C. | $21.69 | 2022 | |
| Novo Nordisk INC | $18.86 | 2025 | Wegovy |
| Ardelyx, INC. | $17.29 | 2024 | Ibsrela |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Waheed Gul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.